Insulin is made in two very different ways, and both are remarkable. Inside the human body, specialized cells in the pancreas build it from scratch as a precursor protein, then clip and fold it into a tiny, precise hormone that controls blood sugar. In pharmaceutical factories, microorganisms engineered with human DNA produce essentially the same molecule in steel fermenters, after which it is purified, refolded, and formulated into the vials and pens that keep hundreds of millions of people with diabetes alive. The overlap between these two processes is striking: nature’s design principles directly shaped industrial production, and the challenges of making insulin in a lab mirror problems the body solved long ago.
How Beta Cells Build Insulin From Scratch
Insulin production begins in the beta cells of the pancreatic islets of Langerhans, small clusters of hormone-producing cells scattered throughout the pancreas. The raw material is a gene on chromosome 11 that encodes not insulin itself, but a larger precursor called preproinsulin. Blood glucose is the main throttle on this process: when glucose rises after a meal, preproinsulin production ramps up dramatically, and when glucose falls between meals, it drops back down.1PubMed Central. Biosynthesis, structure, and folding of the insulin precursor protein
Preproinsulin is essentially insulin with two extra pieces attached. A short “signal peptide” at the front acts like an address label, directing the newly made protein chain into a compartment called the endoplasmic reticulum (ER). Once inside the ER, that signal peptide gets snipped off, leaving proinsulin. Proinsulin is a single chain that still contains a middle segment known as the C-peptide, flanked by what will become the A chain and B chain of mature insulin. Inside the ER, proinsulin folds into its proper three-dimensional shape, locked in place by chemical bonds called disulfide bridges. If the signal peptide isn’t removed properly, or if the folding goes wrong, the misfolded protein gets stuck in the ER and never becomes functional insulin.2PubMed Central. Impaired cleavage of preproinsulin signal peptide linked to autosomal-dominant diabetes
Correctly folded proinsulin moves to the Golgi apparatus and then into secretory granules, small storage packets inside the beta cell. Inside these granules, enzymes cut out the C-peptide, leaving behind the finished two-chain insulin molecule. This final clipping step actually helps the insulin pack tightly into crystalline storage form within the granule, ready for rapid release when the signal comes.3PubMed. Proinsulin endoproteolysis confers enhanced targeting of processed insulin to the regulated secretory pathway
The Glucose Trigger and Insulin Release
A beta cell doesn’t just make insulin and dump it out continuously. It waits for a glucose signal. When blood sugar rises, glucose enters the beta cell and gets metabolized, producing ATP. The rising ratio of ATP to ADP closes potassium channels in the cell membrane, which causes the cell’s electrical charge to shift. That shift opens calcium channels, and calcium floods in.4PubMed. Pancreatic islets from hypothalamic obese rats maintain K+ATP channel-dependent but not -independent pathways on glucose-induced insulin release process The influx of calcium is the final trigger: it causes the insulin-packed granules to fuse with the cell surface and spill their contents into the bloodstream.5PubMed Central. Regulation of insulin exocytosis by calcium-dependent protein kinase C in beta cells
This sequence, glucose metabolism to potassium channel closure to calcium entry to granule release, is often described as the “stimulus-secretion coupling” pathway. It’s an elegant closed loop: the beta cell senses exactly how much glucose is in the blood and calibrates its insulin release accordingly. Specialized potassium channels (called K-ATP channels) sit at the heart of this system, acting as molecular fuel gauges that translate the cell’s metabolic state into an electrical signal.6PubMed Central. KATP Channels and the Metabolic Regulation of Insulin Secretion in Health and Disease Drugs like sulfonylureas, widely prescribed for type 2 diabetes, work by forcing these same channels shut, pushing the beta cell to release more insulin even when glucose isn’t fully driving the process.
Animal Insulin and Its Drawbacks
For decades after insulin’s discovery in 1921, the only way to get therapeutic insulin was to extract it from the pancreases of slaughtered cattle and pigs. The basic method involved grinding up pancreatic tissue, treating it with acid-alcohol to pull out the hormone, and then purifying the extract through filtration and crystallization. This worked well enough to save lives, but it had real problems. Animal insulin isn’t chemically identical to human insulin: porcine insulin differs by one amino acid, and bovine insulin by three. Those small differences meant the immune system sometimes treated injected animal insulin as foreign.
Immunological complications were common in the early decades. Local allergic reactions at injection sites occurred in roughly 5% of patients. High-titer antibodies developed in many people treated with early preparations, which contained not just insulin but contaminants like proinsulin and C-peptide. In some cases, antibody levels got high enough to cause immune-mediated insulin resistance, where the body’s own defenses neutralized the injected hormone. A disfiguring condition called lipoatrophy, where fat tissue at injection sites wasted away, affected anywhere from 10% to 55% of patients on crude bovine/porcine preparations.7PubMed. Immunogenicity and allergenic potential of animal and human insulins Purification technology improved over the years, and switching to highly purified porcine insulin helped considerably, but the fundamental limitation of using a non-human protein remained.
The Recombinant DNA Breakthrough
The story of modern insulin manufacturing really starts in the late 1970s, when scientists at Genentech and City of Hope National Medical Center figured out how to get bacteria to produce human insulin. They didn’t extract the human insulin gene directly from pancreatic cells. Instead, they worked backward from the known amino acid sequence of insulin’s A and B chains, used the genetic code to design corresponding DNA sequences optimized for bacterial production, and then chemically synthesized those genes from scratch using organic chemistry methods available at the time.
Two separate strains of E. coli were each engineered to contain one of the synthetic genes, for the A chain or the B chain, spliced into a gene that the bacteria already expressed abundantly. Each bacterium produced a fused protein: a large bacterial protein linked by a methionine amino acid to a small insulin chain dangling off the end. After partial purification, a chemical called cyanogen bromide was used to cut at the methionine, releasing the insulin chain. The A and B chains were then purified separately and joined together through a chemical reaction that formed the correct disulfide bonds.8PubMed Central. Making, Cloning, and the Expression of Human Insulin Genes in Bacteria: The Path to Humulin
The resulting product, marketed as Humulin and approved by the FDA in 1982, was the first recombinant DNA drug ever sold. It was identical in sequence to human insulin, which largely solved the immunogenicity problems that had plagued animal-derived preparations. That early two-chain approach was somewhat cumbersome, though, and most manufacturers later shifted to producing the entire proinsulin molecule as a single chain in bacteria, then enzymatically removing the C-peptide to yield finished insulin, more closely mimicking what happens in beta cells.
Yeast as an Alternative Production Host
E. coli isn’t the only microorganism used to make insulin. A yeast called Pichia pastoris has become an important alternative, and it offers a key advantage: yeast cells can secrete proteins directly into the surrounding growth medium, which simplifies the initial recovery step enormously. In E. coli, insulin precursors tend to accumulate inside the bacteria as insoluble clumps called inclusion bodies, requiring extra work to dissolve and refold them. Yeast sidesteps that problem.
In a typical Pichia-based process, a synthetic gene encoding an insulin precursor is integrated into the yeast’s genome and paired with a secretion signal borrowed from baker’s yeast. When the yeast grows and is fed methanol as a carbon source, it produces the insulin precursor and pumps it out of the cell into the culture broth. Yields of around 1.5 to 3 grams of insulin precursor per liter of culture have been reported, depending on the strain and fermentation conditions.9PubMed Central. Application of simple fed-batch technique to high-level secretory production of insulin precursor using Pichia pastoris with subsequent purification and conversion to human insulin10Biotechnology and Bioengineering. Human insulin from a precursor overexpressed in the methylotrophic yeast Pichia pastoris and a simple procedure for purifying the expression product The secreted precursor still needs to be enzymatically processed and purified to become finished insulin, but starting with a soluble protein in a clear broth is far simpler than starting with inclusion bodies packed inside bacterial cells.
Novo Nordisk, one of the world’s largest insulin producers, uses a yeast-based manufacturing platform for much of its insulin. The choice between E. coli and yeast isn’t strictly about which is “better” but involves trade-offs in yield, folding efficiency, downstream processing complexity, and existing infrastructure at any given factory.
Downstream Processing and the Challenge of Folding
Regardless of whether E. coli or yeast is the host organism, the raw protein that comes out of the fermenter is not ready for injection. Turning it into pharmaceutical-grade insulin involves a long series of purification and conversion steps that account for much of the cost and complexity of insulin manufacturing.
For E. coli-based production, the process typically starts with harvesting the bacteria, breaking open the cells, and isolating the inclusion bodies containing aggregated proinsulin. Those inclusion bodies are washed, then dissolved using strong chemical agents. The solubilized proinsulin is unfolded and must be refolded into its correct three-dimensional shape with the right disulfide bonds, a step that has historically been one of the biggest bottlenecks.11PubMed Central. Downstream processing of recombinant human insulin and its analogues production from E. coli inclusion bodies Getting three disulfide bonds to form correctly in a test tube, when the wrong pairings can easily form instead, requires carefully controlled conditions. Research into the folding pathway of human proinsulin has identified multiple intermediate forms, each with a different disulfide arrangement, that can reshuffle into the native configuration under the right redox conditions.12Journal of Biological Chemistry. Disulfide-forming Pathway of Human Proinsulin in Vitro
After refolding, the C-peptide is enzymatically removed using trypsin and carboxypeptidase B, mimicking the enzymes that do the same job inside beta cell granules. This conversion produces a two-chain molecule that closely resembles native insulin.13PubMed. Studies on the conversion of proinsulin to insulin. I. Conversion in vitro with trypsin and carboxypeptidase B Multiple rounds of chromatographic purification follow, separating the correctly folded insulin from misfolded variants, residual enzymes, and host-cell contaminants. The final product is typically crystallized with zinc and formulated with preservatives before filling into vials, cartridges, or pen devices. Quality-control testing uses high-performance liquid chromatography (HPLC) to confirm purity and identity.14PubMed. Less is more: Validating a single method for comprehensive rh-insulin analysis
Insulin Analogs and How They Differ
Standard recombinant human insulin behaves just like the insulin your body makes, including its tendency to form clusters of six molecules (hexamers) in solution. That clustering slows absorption from an injection site, creating a lag between injection and blood-sugar-lowering effect. For mealtime coverage, patients ideally want insulin that works fast. For background coverage between meals and overnight, they want insulin that releases slowly and steadily. Analog insulins were designed to solve both problems by tweaking the amino acid sequence just enough to change the molecule’s physical behavior without altering its biological activity.
Rapid-acting analogs like lispro, aspart, and glulisine were created by making amino acid substitutions at the points where insulin molecules stick together. These changes weaken the tendency to form dimers and hexamers, so the molecules break apart faster after injection and reach the bloodstream sooner.15The Journal of Clinical Endocrinology & Metabolism. New Horizons: Next-Generation Insulin Analogues: Structural Principles and Clinical Goals People taking these analogs can inject closer to the start of a meal and get better post-meal glucose control.
Long-acting analogs take the opposite approach. Insulin degludec, for example, has a fatty acid chain attached to it. In the pharmaceutical vial, degludec molecules sit in pairs of hexamers (dihexamers). After injection, phenol from the formulation diffuses away, and the molecules rearrange into long multi-hexamer chains that form a depot under the skin. Insulin monomers slowly peel off these chains over a period well exceeding 24 hours, providing a flat, steady baseline of insulin.16PubMed Central. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin17PubMed Central. Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin? The reduced variability in absorption from day to day is a genuine clinical advantage, since unpredictable insulin action is a major driver of hypoglycemia.
Keeping Insulin Stable in the Vial
One underappreciated challenge is keeping insulin from falling apart before it ever reaches a patient. Insulin is a small protein, and like all proteins, it can clump, denature, or lose activity when exposed to heat, agitation, or microbial contamination. Commercial insulin formulations contain zinc (which promotes the protective hexamer structure), phenolic preservatives like metacresol (which both stabilize the hexamer and prevent bacterial growth), and buffering agents to maintain the right pH.
Researchers are exploring ways to make insulin formulations more robust, especially for situations where cold-chain storage isn’t reliable. One experimental approach replaces zinc and metacresol with an antimicrobial called phenoxyethanol and a synthetic polymer stabilizer. In laboratory stress tests, lispro insulin formulated with this polymer remained stable for roughly 36 to 42 hours under accelerated degradation conditions, compared to about 6 hours for commercial Humalog. Higher concentrations of the polymer pushed stability even further, past 140 hours.18PubMed Central. Formulation Excipients and Their Role in Insulin Stability and Association State in Formulation That kind of improvement could matter enormously in tropical climates or disaster-relief settings where refrigeration is spotty.
Biosimilar Insulins and Regulatory Pathways
As patents on original insulin products expire, biosimilar insulins have entered the market. A biosimilar is not a generic drug in the traditional sense. Small-molecule generics are chemically identical to the original, but biological drugs are made by living cells, and no two manufacturing processes produce a perfectly identical protein. Biosimilar approval therefore requires a stepwise demonstration of similarity: detailed analytical comparison showing the biosimilar’s structure, purity, and potency match the reference product, followed by preclinical and clinical studies confirming equivalent safety and effectiveness.19PubMed Central. Understanding Biosimilar Insulins – Development, Manufacturing, and Clinical Trials
Both the FDA and European Medicines Agency have established specific regulatory pathways for biosimilar insulins. The arrival of biosimilars has put downward pressure on insulin prices in some markets, though the degree of savings varies widely by country. In the United States, where insulin costs have been a source of intense public frustration, biosimilar and follow-on insulin products have slowly begun to expand options, though systemic pricing issues extend well beyond manufacturing.
Smart Insulin and Oral Delivery
The ultimate goal for many researchers is insulin that manages itself: a formulation or analog that senses glucose and adjusts its own activity accordingly, mimicking the beta cell’s built-in feedback loop. These “glucose-responsive” or “smart” insulin systems have been under investigation for over four decades. The concept is straightforward: embed insulin in or attach it to a material that changes its structure when glucose levels rise, releasing more insulin when it’s needed and less when it isn’t.20PubMed Central. Glucose-Responsive Materials for Smart Insulin Delivery: From Protein-Based to Protein-Free Design Some approaches use glucose-binding proteins or enzymes as sensors; others use synthetic chemistry to build glucose-sensitive polymers. None has reached routine clinical use yet, but several are in early-stage human trials.
A separate line of research aims to make insulin swallowable, eliminating injections altogether. The stomach and intestine are hostile environments for a protein drug: digestive enzymes would break it down, and the intestinal lining isn’t designed to absorb large molecules intact. Experimental nanoparticle carriers have shown promise in animal studies. One design uses layered nanoparticles with a chitosan core surrounded by a lipid shell coated with a hydrophilic polymer. In diabetic rats, these particles delivered orally produced blood-sugar-lowering effects roughly 2.5 times greater than an earlier nanoparticle design, and cellular uptake of the encapsulated insulin was 36-fold higher than free insulin alone.21PubMed. Intestinal mucosa permeability following oral insulin delivery using core shell corona nanolipoparticles Translating those results to humans remains a steep challenge, but the work illustrates how far formulation science is reaching beyond the traditional vial-and-needle model.
Why Manufacturing Complexity Matters to Patients
People who use insulin daily rarely think about how it gets from a fermenter to a pharmacy shelf, but the manufacturing process has direct consequences they can feel. The refolding step, for instance, is one reason insulin is expensive to produce compared with simpler biologic drugs: getting those disulfide bonds right at industrial scale requires costly reagents, careful process control, and significant quality testing. Every analog has its own manufacturing quirks. Degludec’s fatty acid attachment requires a chemical conjugation step that doesn’t exist for regular human insulin. Rapid-acting analogs need slightly different purification conditions because their altered amino acids change the molecule’s behavior on chromatography columns.
The complexity also explains why insulin can’t simply be made in any generic pharmaceutical plant. Biologic manufacturing requires specialized fermentation equipment, clean-room filling lines, cold-chain logistics, and analytical laboratories capable of detecting subtle differences between correctly and incorrectly folded protein. Building a new insulin production facility from scratch takes years and costs hundreds of millions of dollars, which is part of why the market has historically been dominated by just a handful of companies. Biosimilar entrants and newer manufacturers are gradually widening the field, but the barrier to entry remains high, and for many patients around the world, access to affordable insulin is still a pressing and unresolved problem.